Hologic (HOLX) announced that its Aptima HPV Assay received FDA approval for clinician-collected HPV primary screening. Hologic’s human papillomavirus test is the only FDA-approved mRNA-based assay, designed specifically to detect infections most likely to lead to cervical cancer.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOLX: